A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours

BACKGROUND: This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimus-resistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436). PATIENTS AND METHODS: In stage 1, 11 patients received 400 mg BEZ23...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Anticancer Res
Main Authors: FAZIO, NICOLA, BUZZONI, ROBERTO, BAUDIN, ERIC, ANTONUZZO, LORENZO, HUBNER, RICHARD A., LAHNER, HARALD, DE HERDER, WOUTER W., RADERER, MARKUS, TEULÉ, ALEXANDRE, CAPDEVILA, JAUME, LIBUTTI, STEVEN K., KULKE, MATTHEW H., SHAH, MANISHA, DEY, DEBARSHI, TURRI, SABINE, AIMONE, PAOLA, MASSACESI, CRISTIAN, VERSLYPE, CHRIS
Format: Artigo
Sprog:Inglês
Udgivet: 2016
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5076549/
https://ncbi.nlm.nih.gov/pubmed/26851029
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker